+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neurodegenerative Drugs Market by Drug Class (Cholinesterase Inhibitors, Decarboxylase Inhibitors, Dopamine Agonist), Indication (Alzheimer's Disease, Dementia, Huntington's Disease), Sales Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888919
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neurodegenerative Drugs Market size was estimated at USD 41.84 billion in 2023, USD 45.91 billion in 2024, and is expected to grow at a CAGR of 8.67% to reach USD 74.93 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neurodegenerative Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neurodegenerative Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neurodegenerative Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACADIA Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Aquinnah Pharmaceuticals, AstraZeneca PLC, AZTherapies, Inc., Bausch Health Companies Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer, Inc., Prevail Therapeutics Inc. by Eli Lilly and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, and UCB S.A.

Market Segmentation & Coverage

This research report categorizes the Neurodegenerative Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cholinesterase Inhibitors
    • Decarboxylase Inhibitors
    • Dopamine Agonist
    • Immunomodulators
  • Indication
    • Alzheimer’s Disease
    • Dementia
    • Huntington’s Disease
    • Motor Neurone Disease
    • Parkinson’s Disease
    • Prion Disease
    • Spinal Muscular Atrophy
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Neurodegenerative Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neurodegenerative Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Neurodegenerative Drugs Market?
  4. What is the market share of the leading vendors in the Neurodegenerative Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Neurodegenerative Drugs Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Neurodegenerative Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising awareness about neurological disorders and need of early diagnosis & treatment
5.1.1.2. Increasing investment in healthcare sector to improve healthcare accessibility
5.1.2. Restraints
5.1.2.1. Complexities & risk associated with the neurodegenerative treatment
5.1.3. Opportunities
5.1.3.1. Ongoing research & development activities for neurodegenerative drugs
5.1.3.2. Increasing number of drug approval by regulatory authorities
5.1.4. Challenges
5.1.4.1. Severe side effects associated with the consumption of neurodegenerative drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Neurodegenerative Drugs Market, by Drug Class
6.1. Introduction
6.2. Cholinesterase Inhibitors
6.3. Decarboxylase Inhibitors
6.4. Dopamine Agonist
6.5. Immunomodulators
7. Neurodegenerative Drugs Market, by Indication
7.1. Introduction
7.2. Alzheimer’s Disease
7.3. Dementia
7.4. Huntington’s Disease
7.5. Motor Neurone Disease
7.6. Parkinson’s Disease
7.7. Prion Disease
7.8. Spinal Muscular Atrophy
8. Neurodegenerative Drugs Market, by Sales Channel
8.1. Introduction
8.2. Offline
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3. Online
9. Americas Neurodegenerative Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Neurodegenerative Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Neurodegenerative Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. ACADIA Pharmaceuticals Inc.
13.1.4. Amneal Pharmaceuticals, Inc.
13.1.5. Aquinnah Pharmaceuticals
13.1.6. AstraZeneca PLC
13.1.7. AZTherapies, Inc.
13.1.8. Bausch Health Companies Inc.
13.1.9. Biogen Inc.
13.1.10. Boehringer Ingelheim International GmbH
13.1.11. Denali Therapeutics Inc.
13.1.12. GlaxoSmithKline PLC
13.1.13. H. Lundbeck A/S
13.1.14. Johnson & Johnson Services, Inc.
13.1.15. Kyowa Kirin International plc
13.1.16. Lupin Limited
13.1.17. Merck & Co., Inc.
13.1.18. Novartis AG
13.1.19. Orion Corporation
13.1.20. Pfizer, Inc.
13.1.21. Prevail Therapeutics Inc. by Eli Lilly and Company
13.1.22. Sanofi S.A.
13.1.23. Takeda Pharmaceutical Company Limited
13.1.24. Theravance Biopharma
13.1.25. UCB S.A.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. NEURODEGENERATIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. NEURODEGENERATIVE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NEURODEGENERATIVE DRUGS MARKET DYNAMICS
FIGURE 7. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 11. NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEURODEGENERATIVE DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NEURODEGENERATIVE DRUGS MARKET SIZE, BY HUNTINGTON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NEURODEGENERATIVE DRUGS MARKET SIZE, BY MOTOR NEURONE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRION DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEURODEGENERATIVE DRUGS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 21. NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 37. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 63. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 132. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 148. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 152. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 192. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 193. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. NEURODEGENERATIVE DRUGS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aquinnah Pharmaceuticals
  • AstraZeneca PLC
  • AZTherapies, Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Denali Therapeutics Inc.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer, Inc.
  • Prevail Therapeutics Inc. by Eli Lilly and Company
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 45.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 74.93 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal

Related Topics

Related Reports

Neurodegenerative Disorder Therapeutics Global Market Report 2024 - Product Image

Neurodegenerative Disorder Therapeutics Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Neurodegenerative Drugs - Global Strategic Business Report - Product Image

Neurodegenerative Drugs - Global Strategic Business Report

  • Report
  • 344 Pages
  • Global
From
Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Neurodegenerative Diseases Drugs Market Report and Forecast 2024-2032 - Product Image

Neurodegenerative Diseases Drugs Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Neurodegenerative Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Neurodegenerative Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From

About the Neurodegenerative Disease Drug Market

The Neurodegenerative Disease Drug market is a subset of the Central Nervous System Drugs market, which focuses on treatments for diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These drugs are typically used to slow the progression of the disease, improve symptoms, and improve quality of life. Common treatments include cholinesterase inhibitors, glutamate antagonists, and dopamine agonists. The Neurodegenerative Disease Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.